Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

n as D9902B) clinical trial

designed to assess the safety and efficacy of the investigational

active cellular immunotherapy PROVENGE(R) (sipuleucel-T) in men with

metastatic androgen-independent prostate cancer. While Dendreon

remains blinded to the data, the independent data monitoring

committee (IDMC) reported to Dendreon a 20 percent reduction in the

risk of death in the PROVENGE arm relative to placebo (Hazard

Ratio= 0.80; 95% Confidence Interval [0.610-1.051]). The IDMC

observed no safety concerns and recommended that the study continue

to its final analysis, which is expected to be completed in mid-2009.

* Presented preclinical data on the Company's lead small molecule

candidate, D-3263, which targets Trp-p8 (a transmembrane cation

channel protein also known as Trp-M8), supporting Trp-p8 as a

therapeutic cancer target. Dendreon plans to file an Investigational

New Drug (IND) application later this year with the U.S. Food and

Drug Administration (FDA) to evaluate D-3263 in a Phase 1 dose

escalation study in cancer.

* Initiated a Phase 2 trial of PROVENGE called ProACT (PROstate Active

Cellular Therapy) or P07-2. The multicenter trial is enrolling 120

patients with metastatic, androgen independent prostate cancer.

* Initiated a Phase 2 trial of PROVENGE in men with localized prostate

cancer who are scheduled to undergo a radical prostatectomy. The

single-center trial called NeoACT (NEOadjuvant Active Cellular

immunoTherapy), or P07-1, which is being conducted at UCSF Helen

Diller Family Comprehensive Cancer Center, is enrolling

approximately 40 patients.

* In lieu of Dendreon's regularly scheduled quarterly conference call,

the Company will present at two upcoming investor c
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... WARRINGTON, Pa. , Oct. 1, 2014 /PRNewswire/ ... the Company has been awarded a Phase II ... up to $3.0 million from the National Institute ... National Institutes of Health (NIH) to support the ... surfactant as a medical countermeasure to mitigate acute ...
(Date:10/1/2014)... Md. , Oct. 1, 2014  Spherix ... to the fostering and monetization of intellectual property, ... litigation against VTech and Uniden in the U.S. ... Texas has been rescheduled for ... for October 2, 2014.  The Court Order setting ...
(Date:10/1/2014)... The participants committed to not only ... their own time adjusting, tweaking and testing virtual models ... ready for judging. , “I enjoyed being involved as ... “The entries showed a commendable range exploring the ... the print medium and the creativity of the contestants.” ...
(Date:10/1/2014)... Washington, USA (PRWEB) September 30, 2014 ... yet efficient arrangements that have evolved in nature over ... biomimetic and bioinspired materials for applications in biophotonics ... Biomedical Optics . The journal is published by SPIE, ... SPIE Digital Library. Several of the peer-reviewed articles are ...
Breaking Biology Technology:Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Array Architects Challenges Staff to Create with 3D Printer 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3
... , , PRINCETON, N.J., July 24 ... companies from around the world who gather at InformexUSA 2010 will ... past, allowing them to connect more precisely with others in their ... The show opens February 16, 2010 in San Francisco, with a ...
... , SILVER SPRING, Md., July 24 ... that it will release its 2009 second quarter financial results ... , United Therapeutics Corporation will host ... a.m. Eastern Time. The teleconference is accessible by dialing ...
... ... offers Fetal Bovine Serum (FBS) originating from abattoirs located in the US, ... treatments such as heat inactivation, dialysis, or gamma irradiation are available as ... FBS for embryonic stem cell research. Each FBS order includes a ...
Cached Biology Technology:Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 2Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 3Spectrum Announces Fetal Bovine Serum Product Line 2
(Date:9/30/2014)... 30, 2014 Winners of The Economist,s prestigious ... scheduled to take place at the JW Marriott Hong Kong on ... winners will share their experiences and the lessons those hold for ... proven innovation over the past decade, will be presented at a ... the summit. It will be the first time the ceremony has ...
(Date:9/29/2014)... tar tended to be lower for smokers of slim ... nicotine tended to be lower. , Slim cigarettes are ... around the world. Previous studies have shown that the ... these cigarettes are lower than those in regular cigarettes. ... are not necessarily linked to a reduced exposure to ...
(Date:9/29/2014)... Monday, September 29: Between 1970 and 2010 ... around the globe dropped 52 percent, says the ... Wildlife Fund (WWF). This biodiversity loss occurs disproportionately ... use of high-income countries. , In addition to ... data point to other warning signs about the ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Slim cigarette smokers not exposed to more harmful chemicals 2Half of global wildlife lost, says new WWF report 2
... mighty animal sounds are all around us. In a few ... discussed and heard at the largest meeting ever devoted to ... Monday June 30 through Friday July 4 at the Palais ... one dimension of Acoustics ,08 Paris. It is the field ...
... engineer who has developed optical technology shown to be ... received a $7.5 million grant over five years from ... that potentially could become a routine colon cancer screening ... cancer is the second-leading cause of cancer deaths in ...
... 25, 2008 An authority on the quality ... consumers and municipal water supply systems, including unexpected ... first of a special series of podcasts from ... scientific society. Marc Edwards, Ph.D., notes that ...
Cached Biology News:Killer whales, blind bats, discriminating dolphins, mating birds 2Killer whales, blind bats, discriminating dolphins, mating birds 3Killer whales, blind bats, discriminating dolphins, mating birds 4Killer whales, blind bats, discriminating dolphins, mating birds 5Killer whales, blind bats, discriminating dolphins, mating birds 6Killer whales, blind bats, discriminating dolphins, mating birds 7Killer whales, blind bats, discriminating dolphins, mating birds 8Killer whales, blind bats, discriminating dolphins, mating birds 9Killer whales, blind bats, discriminating dolphins, mating birds 10Killer whales, blind bats, discriminating dolphins, mating birds 11Killer whales, blind bats, discriminating dolphins, mating birds 12Killer whales, blind bats, discriminating dolphins, mating birds 13Killer whales, blind bats, discriminating dolphins, mating birds 14NCI grant launches clinical trials for colon cancer screening 2NCI grant launches clinical trials for colon cancer screening 3Global Challenges/Chemistry Solutions debuts with focus on drinking water 2
... exchange media are hydrophilic, ... binding capacity. The UNOsphere ... strong cation exchanger with ... 120 micrometers. Fully supported ...
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (Z71,487-9) or contact ... clarifier: centre neck 100 mm, No. ...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
... S-X media are neutral, porous ... exclusion chromatography of lipophilic polymers ... organic eluents. The beads are ... carbon tetrachloride, dimethylformamide, ketones, aromatics, ...
Biology Products: